Researchers have developed a promising targeted strategy to treat chemotherapy-resistant acute myeloid leukemia (AML) and a diagnostic test to determine which AML patients would most likely benefit from this treatment. In a mouse model, the experimental treatment eliminated all signs of disease (complete remission) in 100 percent of animals, while those that received the standard treatment all died.